52214-84-3Relevant articles and documents
Cyclopropanecarboxylic bethe synthetic method
-
Paragraph 0014, (2018/04/01)
The invention relates to a synthesis method of ciprofibrate. In the synthesis method, acetic acid-4-(2,2-dichlorocyclopropyl) phenyl ester is adopted as a raw material, and 2-[4-(2,2-dichlorocyclopropyl) phenoxy]-2-methylpropanoic acid is obtained through alcoholysis, alkylation and alkaline hydrolysis processes. The synthesis method of ciprofibrate, provided by the invention, has the benefits that the raw materials used in the whole reaction are inexpensive and easy to get, the reaction conditions are mild, the operation is convenient, the yield is good, all solvents used in the reaction can be recycled, and the environmental pollution degree is low.
Synthetic method of lipid-lowering drug ciprofibrate
-
Paragraph 0022; 0054; 0055; 0056; 0063; 0071; 0079, (2017/09/01)
The invention provides a synthetic method of lipid-lowering drug ciprofibrate. The synthetic method comprises the following steps: catalyzing reaction of p-hydroxy benzaldehyde and propane diacid in a mixed solvent by virtue of alkali, so as to generate p-hydroxystyrene; catalyzing reaction of p-hydroxystyrene, acetone, chloroform and alkali by virtue of a phase transfer catalyst, so as to generate an intermediate 2-methyl-2-(4-vinylphenoxy)propionic acid; and reacting 2-methyl-2-(4-vinylphenoxy)propionic acid with TiCl4, Mg and CCl4, so as to generate ciprofibrate. The synthetic method has the beneficial effects that the reaction route is short, the raw materials are cheap and easily available, reaction conditions are mild, the energy consumption is reduced, and the production cost is lowered; the post-processing step is simple, the emission of three wastes is reduced, and the method is environment-friendly and safe. Compared with routes of predecessors, the synthetic method has the advantages that the reaction selectivity and conversion rate of the route are relatively high, the wasting of the raw materials is reduced, and the economical efficiency is relatively high.
A method for preparing the fat cumaric acupoint of the c bethe method
-
, (2017/10/07)
The invention discloses a method for preparing a hypolipidemic medicine ciprofibrate with p-coumaric acid. The method comprises the following specific steps: p-coumaric acid (I) is subjected to a decarboxylation reaction under the effect of an alkaline catalyst, such that p-hydroxystyrene (II) is obtained; p-hydroxystyrene (II) is subjected to a reaction with 2-haloisobutyrate under the effect of alkali, such that an etherified product (III) is obtained; under an alkaline condition, the etherified product (III) and chloroform are subjected to a cyclization reaction under the effect of a phase transfer catalyst, such that a cyclized product (IV) is obtained; the cyclized product (IV) is subjected to alcoholysis and acidification in an alkali solution; and recrystallization is carried out, such that ciprofibrate (V) is obtained. The method provided by the invention has the advantages of short synthesis process, safe operation and easy post-treatment. The method is suitable for large-scale industrialized productions, and almost has no possibility of causing accidents such as explosion. During the entire reaction process, only conventional acid, alkali and solvent are used, such that the cost is low. The solvent can be recovered and reused, such that the method is environment-friendly. With the method, the yield is improved by more than 20%.
A new method for synthesizing cyclopropanecarboxylic Bethe
-
, (2018/02/04)
The invention discloses a novel ciprofibrate synthesis method. The novel ciprofibrate synthesis method comprises the specific steps that p-hydroxy benzaldehyde (I) and malonic acid perform condensation decarboxylation reaction in the presence of an alkaline catalyst to obtain p-hydroxystyrene (II), the p-hydroxystyrene (II) reacts with 2-halogenated isobutyrate under the action of alkali to obtain an etherification product (III), the etherification product (III) and chloroform perform cyclization reaction under the alkaline condition and under the action of a phase transfer catalyst to obtain a cyclization product (IV), and the cyclization product (IV) is subjected to alcoholysis, acidification and recrystallization in an alkaline solution to obtain ciprofibrate (V). The novel ciprofibrate synthesis method comprises few synthesis steps, industrial operation is simple and convenient, the conditions are moderate and are easy to control, almost no possibility of explosion and other accidents exists, operation is safe, aftertreatment is convenient, a process is stable, large-scale industrial production is easy to achieve, only conventional acid, alkali and solvents are used in the whole reaction process, the novel ciprofibrate synthesis method is low in cost and is environmentally friendly, and the yield is improved by above 15%.
Treatment of skin conditions by use of PPAR alpha activators
-
, (2008/06/13)
Disorders of the skin and mucous membrane that have a disrupted or dysfunctional epidermal barrier are treated or prevented by topical application of compounds that are either activators of the farnesoid X receptor, activators of the peroxisome proliferator-activated receptor alpha , and oxysterol activators of the LXR alpha receptor. The same compounds are also effective in treating disorders of epidermal differentiation and proliferation.
FXR, PPARA and LXRA activators to treat acne/acneiform conditions
-
, (2008/06/13)
Acne vulgaris and acneiform skin conditions are treated by the application of compounds that is juvenile hormone III, 7-methyl-9-(3,3-dimethyloxiranyl)-3-methyl-2,6-nonadienoic acid methyl ester.
Levo-ciprofibrate
-
, (2008/06/13)
Levo-ciprofibrate or a pharmaceutically acceptable salt thereof is disclosed.
Dextro-ciprofibrate
-
, (2008/06/13)
Dextro-ciprofibrate or a pharmaceutically acceptable salt thereof is disclosed.
Method for the preparation of fibrates
-
, (2008/06/13)
The present invention relates to a method for the preparation of fibrates of the formula I according to the mechanism: STR1 in which R1 represents especially a halogen atom (in particular F, Cl or Br, the preferred halogen atom being Cl) or an acetyl, (4-chlorophenyl)hydroxymethyl, 4-chlorobenzoyl or 2-(4-chlorobenzamido)ethyl group and R2 represents a C1 -C4 alkyl group in which the hydrocarbon chain is linear or branched, the reaction V+VI being carried out without a solvent.
Halocyclopropyl substituted phenoxyalkanoic acids
-
, (2008/06/13)
Halocyclopropyl substituted phenoxyalkanoic acids and esters thereof, having hypocholesteremic activity are prepared via several alternative synthetic approaches, involving as the key reactions interaction of a substituted phenylalkene with a carbene source to introduce the halocyclopropyl moiety, and reaction of a substituted phenol with chloroform and a lower-alkanone in the presence of base, or with a lower-alkyl α-bromo-alkanoate, to form the phenoxyalkanoic acid moiety.
